期刊文献+

肠外营养联合生长激素用于胃肠肿瘤的疗效及安全性评价

Clinical effect and safety of parenteral nutrition and growth hormone in the treatment of gastrointestinal tumor
下载PDF
导出
摘要 目的探究生长激素与肠外营养联合用药治疗的意义,为改善胃肠肿瘤患者生活质量提供理论依据。方法选取90例因胃肠肿瘤入院治疗的患者,按入院时间分为单一组与联合组,每组45例。单一组术后对45例患者给予肠外营养支持,联合组在单一组治疗基础上加用生长激素,观察两组患者能量代谢情况,统计用药期间不良反应发生情况。结果治疗4 d以及8 d后联合组白蛋白指标恢复情况较单一组恢复情况好(P<0.05);单一组不良反应发生率高达17.8%,联合组仅为6.7%。结论肠外营养支持可有效提高患者术后恢复,若与生长激素联合用药,可获得更好疗效且不良反应少。 Objective To study the clinical effect of growth hormone and parenteral nutrition and provide the clinical theory basis on the improvement of life quality for patients with gastrointestinal cancer. Methods 90 patients with gastrointestinal tumor were selected. The subjects were divided into two groups according to the admission time of hospital, 45 cases each group. The single group adopted the parenteral nutrition; the combined group adopted the parenteral nutrition and growth hormone. The energy metabolism and adverse event rate for two groups were observed. Results After 4d and 8d of treatment, the index of albumin for combined group was better than that of single group( P < 0.05). The adverse event rate for single group( 17.8%) was higher than that of combined group( 6.7%). Conclusion The parenteral nutrition support can promote the patient’s fast recovery; the combined therapy of parenteral nutrition support and growth hormone can improve the curative effect and reduce the adverse reactions.
作者 郑桁 ZHENG Heng(Gastrointestinal Surgery of Sichuan Academy of Medical Sciences& Sichuan Provincial People's Hospital ,Chengdu 610072,China)
出处 《中国处方药》 2016年第8期71-72,共2页 Journal of China Prescription Drug
关键词 疗效 胃肠肿瘤 安全 肠外营养 生长激素 Curative effect Gastrointestinal tumor Safety Parenteral nutrition Growth hormone
  • 相关文献

参考文献4

二级参考文献38

  • 1蒿汉坤,华鲁纯,陈宗祜,蔡端,张群华.生长激素和生长抑素对人结肠癌裸鼠移植瘤模型的影响[J].中华实验外科杂志,2006,23(7):784-786. 被引量:9
  • 2迟强,张新宇,王建军,邰升,周令望,曲晓菊,郭惠丽,周佳鹤.重组人生长激素对促进肝硬化大鼠肝脏蛋白质合成的机制[J].中华实验外科杂志,2006,23(9):1134-1134. 被引量:6
  • 3Schricker T,Meterissian S,Lattermann R,et al.Anticatabolic Effects of Avoiding Preoperative Fasting by Intravenous Hypocaloric Nutrition A Randomized Clinical Trial.Annals of Surgery,2008,248:1051-1059.
  • 4Vreeland F,Yin D.Schaaf LJ,et al.Clinical pharmacodynamic efects of the growth hormone receptor antagonist pegvisomant:implications for cancer Therapy.Clin Cancer Res,2007,13:1000-1009.
  • 5Trepp R,Stettler C,Diem P,et al.Effect of Growth Hormone (GH) on Fasting and Postprandial Metabolism in GH Deficiency.Experimental and Clinical Endocrinology & Diabetes 2010,118:596-601.
  • 6Teng Chung T,Hinds CJ.Treatment with GH and IGF-1 in critical illness.Crit Care Clin,2006,22:29-40.
  • 7Kondrup J, Allison SP, Elia M, et al. ESPEN guidelines for nutrition screening 2002. C|in Nutr,2003,22:415-421.
  • 8Bone RC, Balk RA,Cerra FB, el al. Definitions tor sepsis anti organ failure and guidelines for the use of innovali','e therapies in sepsis. The ACCP/SCCM Consensus Conferenee Committee, American College of Chest Physicians/Society of Critieal Care Medicine. 1992. Chest,2009,136 : e28.
  • 9KoretzRl,, l,ipmanTO, Klein S. AGA technical review on parenteral nutrition. Gastroenterology, 2001,121:970-1001.
  • 10Fleyland DK, Montalvo M, Macdonahl S, et al. Total parenteral nutrition in the surgical patient: a meta-analysis. Can J Surg, 2001,44:102-111.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部